Cdkn2B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CDKN2B | |
|---|---|
| Full Name | Cyclin-Dependent Kinase Inhibitor 2B |
| Chromosome | 9p21.3 |
| NCBI Gene ID | 1030 |
| Ensembl ID | ENSG00000147883 |
| OMIM ID | 600431 |
| UniProt ID | P42772 |
| Protein Class | INK4 family (CDK inhibitor) |
| Associated Diseases | Cancer, Cardiovascular Disease, Alzheimer's Disease |
CDKN2B (Cyclin-Dependent Kinase Inhibitor 2B), also known as p15/INK4b, is a key tumor suppressor gene located in the 9p21.3 chromosomal region. This gene encodes a cyclin-dependent kinase inhibitor that regulates cell cycle progression by inhibiting CDK4 and CDK6, thereby controlling the G1 to S phase transition. CDKN2B is a critical component of the INK4b-ARF-INK4a gene cluster, which encodes three essential tumor suppressors: p15, p14(ARF), and p16.
CDKN2B encodes p15, a member of the INK4 (Inhibitor of CDK4) family of proteins. p15 binds to and inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are required for G1 phase progression. When CDK4/6 are inhibited, they cannot phosphorylate the retinoblastoma protein (RB), maintaining RB in its active, growth-suppressive state and preventing S phase entry.
CDKN2B expression is induced by transforming growth factor-beta (TGF-β), making it a key mediator of TGF-β's antiproliferative effects. TGF-β signaling activates SMAD transcription factors that directly upregulate CDKN2B expression, creating a tumor suppressive pathway that halts cell proliferation in response to growth inhibitory signals.
p15 contributes to cellular senescence, an irreversible cell cycle arrest that serves as a barrier to tumorigenesis. By permanently halting cell division in response to oncogenic stress or DNA damage, p15 helps prevent the accumulation of mutations that could lead to cancer.
The CDKN2B promoter is frequently silenced by DNA methylation in cancers. Hypermethylation of the CDKN2B promoter leads to transcriptional repression, removing the CDK4/6 inhibition and allowing uncontrolled proliferation. This epigenetic silencing is observed in numerous cancers including leukemia, colorectal cancer, and gliomas.
CDKN2B operates at the critical G1/S checkpoint of the cell cycle:
CDKN2B is part of a crucial tumor suppressor cluster on chromosome 9p21.3:
This cluster is one of the most frequently altered regions in human cancer.
As a TGF-β-inducible gene, CDKN2B mediates the cytostatic effects of TGF-β:
CDKN2B is frequently inactivated in human cancers:
Genome-wide association studies (GWAS) have identified CDKN2B variants as risk loci for:
The 9p21.3 locus containing CDKN2B is one of the strongest cardiovascular risk loci.
Emerging evidence links CDKN2B to neurodegeneration:
CDKN2B methylation and deletion are common in MDS, contributing to ineffective hematopoiesis and progression to AML.
CDKN2B exhibits tissue-specific expression:
CDKN2B interacts with key cell cycle proteins:
CDKN2B restoration strategies are being explored:
Understanding CDKN2B's role in vascular biology may lead to:
Research directions include:
The study of Cdkn2B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.